Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cetuximab. Found 9 abstracts

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon Ii YM, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016 Dec 27;7(52):86359-73.   PMCID: PMC5341330
Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014 Oct;25(10):2036-41.   PMCID: Pmc4176450
Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. British Journal of Cancer. 2012 Feb;106(4):748-55.   PMCID: PMC3322945
Kim S, Eleff M, Nicolaou N. CETUXIMAB AS PRIMARY TREATMENT FOR CUTANEOUS SQUAMOUS CELL CARCINOMA TO THE NECK. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011 Feb;33(2):286-8.   PMCID: *
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology. 2008 Aug;110(2):140-5.
Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Current Cancer Drug Targets. 2006 Dec;6(8):691-710.
Meropol NJ. Turning point for colorectal cancer clinical trials. JOURNAL OF CLINICAL ONCOLOGY. 2006 Jul;24(21):3322-4.
Psyrri A, Yu ZW, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clinical Cancer Research. 2005 Aug 15;11(16):5856-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cetuximab

Last updated on Wednesday, February 05, 2020